Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 2Terminated 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 2Sarcoma 1Other 1Gastrointestinal 1

Conditions

Neoplasms 5Vipoma 4Carcinoma, Islet Cell 4Somatostatinoma 3Neuroendocrine Tumors 3Intestinal Obstruction 3Insulinoma 3Glucagonoma 3Gastrinoma 3Carcinoma, Hepatocellular 3Thymoma 2Stomach Neoplasms 2Prostatic Neoplasms 2Neoplasm Metastasis 2Meningioma 2Diarrhea 2Carcinoma 2Carcinoid Tumor 2Adenoma, Islet Cell 2Weight Loss 1Waldenstrom Macroglobulinemia 1Vomiting 1Recurrence 1Rectal Neoplasms 1Primary Inoperable Thymoma 1Pleural Effusion 1Pheochromocytoma 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1

Interventions

Octreotide 3Metoclopramide 1Methylprednisolone 1Dexamethasone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Intestinal Obstruction × Octreotide × Clear all
NCT04027348 2022-11-29

Palliative Management of Inoperable Malignant Bowel Obstruction

Roswell Park Cancer Institute

Phase 2 Terminated
15 enrolled 10 charts

Intestinal Obstruction

NCT00004895 2012-06-06

Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery

Northwestern University

Phase 2 Completed
GastrointestinalGynecologicOtherSarcoma

Carcinoma, Ovarian Epithelial, Bile Duct Neoplasms, Colonic Neoplasms, Constipation, Intestinal Obstruction, Nausea, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Vomiting, Colorectal Neoplasms, Gastrointestinal Stromal Tumors

NCT00332696 2011-09-23

Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis

Novartis

Phase 2 Completed
64 enrolled 17 charts
Gynecologic

Carcinoma, Intestinal Obstruction, Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡